Evidence map›Paper›PMID 40993667›Full record

ArticleReproductive biology and endocrinology : RB&E2025

FTO regulates testosterone secretion in Leydig cells: insights into the role of m

Chenglu Wang, Kebing Yang, Fang Gao, Min Zheng, Xiaohua Fu

Abstract read
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chenglu WangCenter for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.
Kebing YangUrology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.
Fang GaoCenter for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.
Min ZhengCenter for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.
Xiaohua FuCenter for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China. reprodw@foxmail.com.

Funding

Medical Science and Technology Project of Zhejiang Province 2023RC002
6 · The paper itself

Abstract

backgroundTestosterone plays a pivotal role in male reproductive health and is synthesized primarily by Leydig cells (LCs) in the testes. Alterations in testosterone levels can lead to sexual dysfunction, reduced fertility, and various systemic health issues. FTO, an m

objectiveThis study aims to investigate the role of FTO in regulating testosterone secretion by LCs and to explore the potential impact of hCG treatment in rescuing the effects of FTO inhibition.

methodsIn this study, we assessed the mRNA and protein expression levels of FTO in LCs from 39 male patients diagnosed with obstructive azoospermia. Additionally, FTO knockdown was performed in TM3 cells, followed by analysis of cell proliferation, apoptosis, and testosterone secretion. The effect of hCG on rescuing FTO inhibition-induced changes was also evaluated.

resultsWe identified a positive correlation between FTO expression levels and testosterone concentrations in LCs from 39 male patients with obstructive azoospermia. FTO knockdown in TM3 cells significantly reduced testosterone secretion, cell proliferation, and increased apoptosis. Specifically, 48 h post-transfection, the apoptosis rate in shRNA-FTO-transfected TM3 cells was 6.26%, significantly higher than in mock-transfected cells (3.03%, P = 0.013). FTO inhibition also markedly suppressed cell proliferation by 26.2% (P < 0.0001) at 24 h, 34.3% (P = 0.0006) at 48 h, and 21.5% (P = 0.002) at 72 h, as measured by CCK-8 assay. However, the addition of 10 IU hCG significantly rescued the proliferation and reduced the apoptosis rate in the FTO knockdown group. Testosterone secretion in the FTO inhibition group was also significantly lower than in controls at all time points (6, 24, 48, and 72 h), but hCG treatment restored testosterone levels by 26.4% (P = 0.003) at 6 h, 29.4% (P = 0.0026) at 24 h, 18.8% (P = 0.028) at 48 h, and 36.6% (P = 0.0005) at 72 h.

conclusionOur study provides new evidence that FTO plays a critical role in regulating testosterone secretion in LCs. Additionally, we demonstrate that hCG treatment can restore testosterone production impaired by FTO inhibition. These findings offer valuable insights into the molecular mechanisms underlying testosterone secretion and may inform therapeutic strategies for male infertility and hypogonadism.

Indexed as

AdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOAzoospermiaChorionic GonadotropinLeydig CellsTestosteroneAdultAnimalsApoptosisCell ProliferationHumansMaleMiceAdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOChorionic GonadotropinFTO protein, humanN-methyladenosineTestosteroneFTOHCGLeydig cellsM6A modificationTestosterone secretion

Identifiers

PMID40993667
PMCPMC12462280

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.